AI assistant
Sending…
VYNE Therapeutics Inc. — Director's Dealing 2021
Jul 20, 2021
35290_dirs_2021-07-20_9641d2a8-312b-4b2d-b800-6c00266019bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-07-19
Reporting Person: Sandoval Elisabeth (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-19 | Stock Options | $2.75 | A | 20500 | Acquired | 2031-07-19 | Common Stock (20500) | Direct |
Footnotes
F1: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.